INTRODUCTION
============

Independent genome-wide association studies (GWAS) have identified multiple risk regions for many epithelial cancers in the gene-poor region of chromosome 8q24 ([@b8-0050366]; [@b11-0050366]; [@b21-0050366]; [@b29-0050366]). We ([@b14-0050366]; [@b18-0050366]) and others ([@b22-0050366]; [@b26-0050366]; [@b27-0050366]) have identified enhancers in this region that loop to the potent oncogene *Myc*, located 200--400 kb telomeric ([@b1-0050366]; [@b27-0050366]), providing a plausible mechanism for risk. One of these enhancers, originally identified by ChIP-chip analysis as a histone H3 acetylation peak and designated AcP10 ([@b14-0050366]), contains a risk single nucleotide polymorphism (SNP; rs6983267); a G in this position is significantly associated with the pathogenesis of prostate, colorectal and other cancers. The significance for prostate cancer risk among Caucasians has one of the lowest GWAS *P*-values (*P*=6.2×10^−23^) ([@b3-0050366]). The risk-associated SNP allele also facilitates increased binding of transcription factor 7-like 2 (TCF7L2) ([@b18-0050366]; [@b22-0050366]) and confers on AcP10 higher enhancer activity. Although AcP10 loops to *Myc* ([@b1-0050366]; [@b27-0050366]), extensive expression quantitative trait locus (eQTL) analyses in prostate and colorectal tumors and in normal tissues have failed to demonstrate any association between risk haplotypes and levels of *Myc* expression ([@b18-0050366]; [@b19-0050366]; [@b22-0050366]; [@b27-0050366]). Apart from this intriguing but still unproven association with *Myc* expression, the cellular and molecular mechanisms underlying the increased prostate cancer risk mediated by AcP10 remain unclear. Recently, Wasserman et al. carried out a bacterial artificial chromosome (BAC) transgenic survey of the 8q24 region in which they identified a 5 kb genomic fragment spanning rs6983267 that was active in the mouse prostate ([@b26-0050366]). Stains of whole prostates from postnatal day 21 (P21) mice suggested overlap in *Myc* and transgene expression; however, no histological analysis was performed, leaving identification of the cell type in which the transgene was expressed unclear. Here we document a link between AcP10 activity and a subpopulation of prostate cells that is both a stem population and a potential cell of origin of prostate cancer.

The prostate contains three epithelial cell types: lumenal secretory cells, basal cells and neuroendocrine cells ([@b17-0050366]). Prostate stem cells have been initially identified within the basal cell population ([@b10-0050366]), but androgen depletion and replenishment experiments have demonstrated the presence of stem cells within the lumenal compartment ([@b25-0050366]). The growth and maintenance of the prostate are strongly dependent on androgens ([@b17-0050366]). When androgens are depleted by castration, the prostate undergoes involution. During this process, most lumenal cells, and a smaller percentage of basal cells, are lost. Shen and colleagues ([@b25-0050366]) have identified a population of lumenal epithelial cells that persists after androgen ablation. These cells are characterized by their expression of the homeobox gene *Nkx3.1*, whose expression is regulated by androgens and in turn regulates the development of the prostate epithelium. A functional variant in NKX3.1 is also associated with prostate cancer susceptibility and downregulates its expression ([@b2-0050366]). In normal adult mice, Nkx3.1 is expressed in most or all lumenal cells. Despite its expression-dependence on androgens, a small population of Nkx3.1-positive cells remains after androgen depletion. These cells, designated castration-resistant Nkx3.1-positive (CARN) cells, are capable of giving rise to all three prostate epithelial lineages ([@b25-0050366]). Moreover, these cells can serve as a cell of origin in PTEN-mediated prostate cancer development in mice ([@b25-0050366]).

In the present study, we used a transgenic approach to assess the cell-type specificity of AcP10 activity. We show that a 1.5 kb fragment, spanning the rs6983267 ancestral and risk G allele, contains a DNA sequence with exceptionally highly conservation in mammals, birds and reptiles. We further show that, in mice, this sequence directs reporter gene expression to a small subset of epithelial cells of the prostate, colon, breast and skin, but not to cells of the lung or liver. Androgen ablation experiments suggest, strikingly, that AcP10 is active in CARN cells. It is also active in a subset of Myc-expressing cells. Our results provide a plausible mechanism as to how AcP10 can influence cancer risk: by affecting the *Myc* pathway in a set of cells crucial for prostate growth and tumorigenesis.

RESULTS
=======

The AcP10 enhancer region is highly conserved among vertebrates
---------------------------------------------------------------

To identify conserved and thus potentially functional DNA elements in the AcP10 region, we compared syntenic DNA segments across diverse vertebrate groups ([Fig. 1](#f1-0050366){ref-type="fig"}). We identified a sequence of 1750 nucleotides that was highly conserved among placental and marsupial mammals. This sequence contained a core of 450 nucleotides that was significantly conserved in mammals, reptiles and birds. The functional SNP, rs6983267, shown previously to be causally associated with risk of prostate cancer ([@b11-0050366]), lay just outside this core sequence, within the region exhibiting conservation among mammals ([Fig. 1A](#f1-0050366){ref-type="fig"}). Interestingly, the ancestral G allele imposes prostate cancer risk in multiple populations and might be related to the known higher risk of prostate cancer among recent descendants of Africans such as African-Americans ([Fig. 1B](#f1-0050366){ref-type="fig"}).

![**Conservation of the AcP10 enhancer in terrestrial vertebrates and geographical distribution of the rs6983267 SNP.** (A) We used software available on the University of California Santa Cruz (UCSC) genome browser to assess the degree of DNA sequence conservation in the region of the AcP10 enhancer. Shown is the Placental Mammal Basewise Conservation assessed by PhyloP (blue vertical lines), and vertebrate Multiz alignment of sequences from rhesus monkey, mouse, dog, elephant, opossum, platypus, chicken, lizard, *Xenopus tropicalis* and stickelback (black vertical lines). The 1.5 kb fragment containing the AcP10 enhancer is indicated by the horizontal line above. The nucleotide sequence of the region surrounding the rs6983267 functional SNP is shown below. Note that all species shown have the G allele. (B) Global distribution of the high-risk G allele and lower risk T allele of rs6983267 as assessed by the UCSC genome browser. Note the prevalence of the G allele in Africa, suggesting that it might have originated there.](DMM008458F1){#f1-0050366}

A conserved AcP10 sequence is sufficient to direct *lacZ* reporter expression to prostate, mammary gland, colon and hair follicle
---------------------------------------------------------------------------------------------------------------------------------

To investigate the mechanism by which AcP10 might influence cancer risk, we asked whether a fragment bearing the conserved region is capable of driving reporter gene expression to specific tissues in transgenic mice. We produced a transgene in which the 1.5 kb fragment was inserted in a vector containing the hsp68 minimal promoter and *lacZ* \[encoding β-galactosidase (β-gal)\] reporter gene. This vector has been used extensively for assessing enhancer activity in vivo ([@b6-0050366]).

![**AcP10 directs reporter gene expression to cells of the prostate, mammary gland, colon and skin.** We produced transgenic mouse lines carrying the AcP10-hsp68-*lacZ* construct. We examined three such lines for transgene expression in mouse tissues (A--H). Tissues were sectioned and stained for β-gal activity (blue) and counterstained with nuclear fast red. (A) Sections of prostate from a control, non-transgenic mouse. (B) Sections of prostate from lines 1, 2 and 3. Note β-gal-positive cells in lumenal epithelium in each line. Line 2 was further examined for β galactosidase expression in the colon (C), mammary gland (D), skin (E), liver (F), lung (G) and spleen (H). Note expression in colon, mammary gland and skin. AP, anterior prostate; DLP, dorsolateral prostate; VP, ventral prostate. Arrows indicate *lacZ*-expressing cells.](DMM008458F2){#f2-0050366}

We injected the construct into mouse zygotes and produced three independent transgenic lines. We examined 8-week-old animals of each line for β-gal expression in a variety of tissues. Representative examples are shown in [Fig. 2](#f2-0050366){ref-type="fig"}. Staining was apparent in prostate, colon, mammary gland and hair follicle. No staining was detected in liver or lung. The tissue distribution of β-gal activity was similar in the three independent transgenic lines ([Fig. 2](#f2-0050366){ref-type="fig"} and data not shown), suggesting that position effects were not the cause of tissue-specific transgene expression.

The AcP10 transgene is expressed in lumenal epithelial cells of the prostate
----------------------------------------------------------------------------

We examined β-gal expression in greater detail in the prostates of line 2. The mouse prostate has three lobes: anterior, dorsolateral and posterior. As is evident in [Fig. 3](#f3-0050366){ref-type="fig"}, β-gal-positive cells were present in all three lobes, but were more abundant in the anterior lobe. Images of sections at higher magnification showed that β-gal-positive cells were located largely, if not exclusively, in the lumenal epithelium ([Fig. 3](#f3-0050366){ref-type="fig"}). Co-staining of sections with an antibody against CK8, a marker for lumenal epithelial cells ([@b28-0050366]), and an antibody against β-gal, showed that all β-gal-positive cells are also positive for CK8 ([Fig. 4](#f4-0050366){ref-type="fig"}). Staining with an antibody against CK5, which marks basal cells ([@b28-0050366]), showed no overlap with β-gal. These results show that the β-gal-positive cells are lumenal epithelial cells.

The AcP10 transgene is expressed in a subset of cells resistant to androgen ablation and positive for Nkx3.1
------------------------------------------------------------------------------------------------------------

Although there is considerable evidence that basal cells contain a stem population ([@b9-0050366]), recent work shows that the lumenal compartment also contains stem cells ([@b25-0050366]). These cells are marked by continued expression of Nkx3.1 after androgen ablation. We asked whether AcP10--β-gal-positive cells also expressed Nkx3.1. We co-stained sections of prostates of AcP10--β-gal transgenic mice with antibodies against β-gal and Nkx3.1. The distribution of AcP10-positive cells in the different lobes of the prostate was unchanged following androgen ablation (data not shown). As reported previously, Nkx3.1 was expressed in all or most lumenal epithelial cells ([@b25-0050366]) ([Fig. 5](#f5-0050366){ref-type="fig"}). Following castration, Nkx3.1-positive cells were reduced to small patches of cells and individual cells, consistent with the findings of Wang et al. ([@b25-0050366]). A comparison of the Nkx3.1 expression pattern with that of AcP10--β-gal showed that the two signals overlapped partially ([Fig. 5F,I](#f5-0050366){ref-type="fig"}). The fact that the overlap was not greater suggested that there was not a simple gene regulatory relationship between AcP10 and Nkx3.1 in which, for example, one is necessary and sufficient for the expression of the other. It remained possible, however, that there was a non-random association between the two. To test this possibility, we counted foci positive for AcP10-driven β-gal and Nkx3.1 individually, and foci positive for both. We used a chi-square (χ^2^) test to investigate whether the number of foci positive for both was greater than expected from chance alone. As is evident from data presented in [Table 1](#t1-0050366){ref-type="table"}, counts performed on four mice consistently showed an association significantly greater than expected, and yielded an overall *P*\<0.001 that the association was due to chance (Mantel-Haenszel test). These data suggest that AcP10 and Nkx3.1 are associated in a regulatory network. The less than perfect correlation between Nkx3.1 and AcP10 expression suggests that this association is complicated by input from additional factors in a complex regulatory network.

![**Expression of AcP10-hsp68-*lacZ*** **transgenic line 2 in different regions of the prostate.** Positive cells were present in the anterior prostate (AP; A,D,G), the dorsolateral prostate (DLP; B,E,H) and the ventral prostate (VP; C,F,I). Higher magnification images show that virtually all positive cells were located in the lumenal epithelium (G--I).](DMM008458F3){#f3-0050366}

AcP10 is active in prostate tumors in mice that have targeted inactivation of *Pten* in the prostate
----------------------------------------------------------------------------------------------------

We next investigated whether AcP10 is active in prostate tumors. We made use of the Pten model of prostate cancer in which the *Pten* tumor suppressor gene is inactivated in the prostate by means of Cre-mediated recombination driven by the prostate-specific probasin-Cre ([@b24-0050366]). Previous work established that probasin-Cre mediates efficient recombination of the floxed *Pten* allele ([@b24-0050366]). In this system, virtually 100% of homozygous mutant mice develop tumors within 9 weeks ([@b24-0050366]). We produced mice homozygous for the floxed *Pten* allele and also carrying probasin-*Cre*. We examined prostates of Pten-probasin-Cre conditional mutants aged 7--9 months. As expected, all mutants examined had prostate tumors (*n*=7). As previously described ([@b24-0050366]), prostates in mutant mice contained regions of normal morphology, as well as areas of prostatic intraepithelial neoplasia (PIN) and frank adenocarcinoma. Counting of β-gal-positive clusters revealed no significant concentration in any of these three tissue types (data not shown). Marker analysis with the basal marker CK5 and the lumenal marker CK8 showed that AcP10-positive tumor cells, like their normal counterparts, co-express CK8 ([Fig. 6](#f6-0050366){ref-type="fig"}); thus loss of Pten function did not influence the cell type in which AcP10 was expressed.

DISCUSSION
==========

Here we address the mechanism by which highly conserved, non-coding DNA elements within the 8q24 gene desert influence cancer risk. Previously we identified a subregion of 8q24, AcP10, that contains a risk SNP and has enhancer activity in cultured cells ([@b14-0050366]). In the present study, we show that a 1.5 kb fragment, including a highly conserved DNA sequence in which the SNP is embedded, directs reporter gene expression to a subset of lumenal epithelial cells in the prostate. These include some cells that persist after androgen ablation and express the transcription factor Nkx3.1. Shen and colleagues demonstrated that these cells, designated castration-resistant Nkx3.1-positive (CARN) cells, are both stem cells and potential cells of origin of prostate cancer ([@b25-0050366]). We show, moreover, that AcP10 is active in cells of prostate tumors developing in mice in which the *Pten* gene is inactivated in the prostate. Our results thus provide a plausible mechanism by which the AcP10 enhancer element can influence prostate cancer risk.

Accumulating evidence shows that highly conserved, non-coding elements (CNEs) can have gene regulatory functions ([@b7-0050366]). The human genome contains many thousands of such elements, which are likely to have originated as retroposons and in some instances have acquired a function in the host genome, a process known as exaptation ([@b20-0050366]). Some CNEs have been shown to function as tissue-specific enhancers. In most but not all cases they are also defined by their extremely high degree of DNA sequence conservation across vertebrates ([@b5-0050366]). At least some CNEs are under negative selection, implying that the extremely high degree of sequence conservation is required for function.

The AcP10 element has a central region approximately 450 bp in length that is conserved across terrestrial vertebrates, exhibiting approximately 67% identity to a sequence in lizards. This high degree of conservation suggests a fundamental and slowly evolving function in vertebrates. Such a function might include controlling gene expression in the prostate or in tissues from which the prostate evolved, such as the Mullerian duct ([@b23-0050366]).

We note that the AcP10 element drives expression in epithelial tissues of the breast, colon and skin, but not in epithelia generally. We have not yet identified the specific cell types in these tissues in which the AcP10 transgene is expressed. This is likely to be of interest at least in the colon because AcP10 is associated with risk of colon cancer as well as prostate cancer.

The fact that the high-risk (G) allele of the SNP rs6983267 is the ancestral allele is evident in comparisons across vertebrates showing the G allele in all groups. It is also apparent in the geographic distribution of the two alleles in humans, which shows the high risk G allele in African populations and the low-risk T allele outside Africa, consistent with the T allele emerging as ancestral humans migrated out of Africa. The T allele might have conferred a selective advantage, perhaps reducing the risk of cancer. Grandparent effects ([@b12-0050366]) on allele frequency -- i.e. selection acting at the level of extended family or group -- could explain fixation of an allele that does not provide a direct advantage to individuals of reproductive age.

![**AcP10 is active in prostate lumenal epithelial cells.** Immunostaining with the basal cell marker CK5 (A,E; green fluorescence) and the lumenal cell marker CK8 (B,F; green fluorescence) showed that β-gal (C--F; red fluorescence) was found exclusively in lumenal cells (compare overlapped images in E and F).](DMM008458F4){#f4-0050366}

An approach that has been used by several groups to identify stem cells in the mouse prostate is to reduce androgen levels by physical or chemical castration and examine the cells remaining after this treatment ([@b25-0050366]). When androgens are withdrawn, the prostate involutes to a small size. Resupplying androgens causes the gland to regenerate. All the cells required to regenerate the gland are most likely present in the involuted gland following androgen ablation. Using this approach, Shen and colleagues ([@b25-0050366]) showed that a subset of lumenal epithelial cells remain in androgen-depleted prostates. These CARN cells are capable of giving rise to an entire prostate, and are also a cell of origin of prostate cancer.

As we noted previously ([@b14-0050366]), AcP10 has chromatin marks consistent with enhancer activity. Moreover, it can function as an enhancer in cultured cells. Thus, we expected AcP10 to drive reporter gene expression in transgenic mice. We were surprised, however, at the remarkable specificity of transgene expression in a subset of prostate epithelial cells. Marker analysis showed that the AcP10--β-gal-positive cells are lumenal. Positive cells tend to be clustered, implying that such cells are clonally related.

Until recently, only basal epithelial cells were thought to contain stem populations and to serve as cells of origin of prostate cancer ([@b9-0050366]). New findings by the Shen group ([@b25-0050366]) that the lumenal compartment might also have stem cells prompted us to investigate whether the AcP10--β-gal-positive cells exhibit molecular characteristics of lumenal epithelial stem cells. Shen and colleagues showed that the transcription factor Nkx3.1 is expressed in all or most lumenal epithelial cells in control mice ([@b25-0050366]). Upon androgen depletion by castration, the prostate is greatly reduced in size, and Nkx3.1 expression is retained in a small subset of lumenal cells. Our results show that about 8.5% of AcP10-positive cells are also positive for Nkx3.1, compared with 3.6% of AcP10-negative cells ([Table 1](#t1-0050366){ref-type="table"}). Chi-square analysis suggests that this overlap in expression patterns is significant (*P*\<0.001).

![**AcP10 is active in a subset of CARN cells.** AcP10-hsp68-*lacZ* line 2 mice were castrated at 2 months after birth. After 2 weeks, prostates were sectioned and the sections co-stained with antibodies against Nkx3.1 (A,D,G) and β-gal (B,E,H). Nkx3.1 (green) was expressed in most or all lumenal epithelial cells of the normal prostate (A). β-gal activity (red) was apparent in a subset of these cells (B). In post-castration prostates (D--I), both Nkx3.1 and β-gal were expressed in a small subset of cells compared with the normal prostate (compare D--I with A--C). Moreover, in a significant number of cells, Nkx3.1 and β-gal expression overlapped (F,I).](DMM008458F5){#f5-0050366}

###### 

Co-expression of AcP10--β-gal and Nkx3.1

![](DMM008458T1)

That AcP10 is not expressed in all Nkx3.1-positive cells suggests that there is not a simple relationship between the enhancer activity of AcP10 and the identity of such cells or the regulation of Nkx3.1. Thus it is not likely that the main function of AcP10 is to regulate the expression of Nkx3.1 in lumenal epithelial cells; nor is it probable that Nkx3.1 is a main determinant of the activity of AcP10 in such cells. Rather, the increased likelihood that AcP10 is expressed in Nkx3.1-positive cells suggests that AcP10 and Nkx3.1 are linked in a regulatory network, although perhaps distantly. Even a distant link, however, could be part of the explanation of how AcP10 increases the risk of prostate cancer. Shen and colleagues ([@b25-0050366]) showed that Nkx3.1-positive cells are also potential cells of origin of prostate cancer in a *Pten* mouse model. Thus, our results connect the AcP10 enhancer to a population of cells that can self renew, produce prostate epithelial cell types after injection into the mouse kidney capsule, and give rise to prostate tumors ([@b25-0050366]).

Our overall hypothesis is that AcP10 controls the expression of a gene(s) whose activity is crucial for tumorigenesis. One possible AcP10-regulated gene is *Myc*. We showed previously that AcP10 loops to *Myc*, and that the risk allele of rs6983267 enhances TCF7L2 binding to the enhancer ([@b18-0050366]). This result led us to predict that *Myc* expression in prostate tumors would correlate with the SNP genotype. We found that this was not the case, however. There was no eQTL relationship between SNP genotype and *Myc* expression in tumors. It remains possible that AcP10 modulates *Myc* expression levels transiently in a tumor precursor cell, an idea also suggested by Wasserman and colleagues ([@b26-0050366]). We carried out immunostaining with an anti-Myc antibody and found that Myc protein was expressed widely in the prostate epithelium (data not shown), consistent with the findings of Wasserman and colleagues ([@b26-0050366]). Although there was some overlap with AcP10 expression, the broad distribution of Myc made it impossible to determine whether this overlap occurred by chance. Clearly, because AcP10 is expressed in few Myc-positive cells, it is not likely to be a principal determinant of Myc expression in the prostate. Nevertheless, AcP10 might have a quantitative effect on Myc expression in a subset of cells. Such an effect could be sufficient to predispose such cells to oncogenic transformation and thus explain the elevated risk of prostate cancer associated with the rs6983267 genotype.

Highly conserved, non-coding elements such as AcP10 are thought to be derived from retroposons ([@b4-0050366]). Although the function of such elements is unclear, at least some undergo exaptation, a process by which they are co-opted as participants in a cellular regulatory process that is beneficial to the host organism ([@b4-0050366]). Such a process might include the acquisition of an ability to regulate gene expression in a tissue-specific manner and thus control cellular identity. AcP10 could be such an element, and AcP10-expressing cells could have a distinct identity and set of properties, perhaps related to prostate function or development. A key unanswered question is whether the association of AcP10 with oncogenesis is related to such a function in normal prostate development, or is a consequence of a fortuitous ability of AcP10 to direct gene expression to the prostate lumenal epithelium.

METHODS
=======

Generation of DNA constructs for microinjection
-----------------------------------------------

An AcP10 (chr8:128482318-128483856; 1538 bp) fragment was released from the AcP10/tk-luc plasmid ([@b14-0050366]) by *Sac*II restriction endonuclease digestion, blunt-filled with Quick Blunting Kit, followed by subcloning into the *Sma*I site of pKSBlue-hsp-*lacZ* vector. Sequencing revealed the proper insertion in the forward direction of the pKSBlue-hsp-*lacZ* vector.

Production and genotyping of transgenic mice
--------------------------------------------

AcP10-pKSBlue-hsp-*lacZ* transgenic mouse embryos and lines were generated in the Norris Cancer Center Transgenic/Knockout Mouse Core by pronuclear injection as described by Liu et al. ([@b16-0050366]). DNA was prepared from mouse tails or embryo yolk sacs and used for genotyping of the *lacZ* allele by PCR as described ([@b15-0050366]).

Pten prostate cancer model
--------------------------

*cPten^−/--^*; AcP10-pKSBlue-hsp-*lacZ* mice were generated by crossing of the prostate-specific *Pten* homozygous-deletion mice with AcP10-pKSBlue-hsp-*lacZ* transgenic mice. The parental male mouse harboring the probasin-*Cre* (PB-Cre4) transgene and floxed *Pten* (f *Pten*) allele was described previously ([@b24-0050366]).

![**AcP10 is active in prostate tumors.** We produced mice with the genotype *AcP10-lacZ; Pten^cko/cko^*; probasin-*Cre*. We examined the prostates of these mice after 5 months when virtually 100% had prostate tumors. We carried out immunostaining for the basal cell marker CK5 (A), the lumenal cell marker CK8 (B) and β-gal (C,D). Overlapped images are shown in E and F. Note clusters of β-gal-positive cells in areas of the prostate that have a tumor phenotype (C,D). Note also that the β-gal signal is found exclusively in cells positive for the lumenal cell marker CK8 (F).](DMM008458F6){#f6-0050366}

###### TRANSLATIONAL IMPACT

**Clinical issue**

The genetic risk factors for prostate cancer remain poorly characterized. 8q24 is a genomic region that has recently been found to have a highly significant association with prostate cancer risk. 8q24 is a gene desert, and the molecular mechanisms by which it might increase cancer risk are unclear. Previous work by this group showed that a risk-associated single nucleotide polymorphism (SNP) within 8q24 (rs6983267) lies within a genomic region with chromatin marks that are associated with active enhancers. This region, designated AcP10, was found to have enhancer activity in cultured cells.

**Results**

Now, the authors report on the function of AcP10 in vivo to further elucidate how this region confers prostate cancer risk. They show that a 1.5 kb fragment spanning the risk-associated SNP drives reporter gene expression in a subset of lumenal epithelial cells in the mouse prostate. These cells have characteristics of a recently identified population of stem cells, in that they remain after castration and express the marker gene *Nkx3.1*. Other work has shown that castration-resistant *Nkx3.1*-expressing cells have stem-like properties and are a cell of origin for prostate tumors in a *Pten* knockout mouse model.

**Implications and future directions**

This work documents that AcP10 is an enhancer that can drive reporter expression in a population of putative stem cells in the prostate. Identifying the genes and processes regulated by AcP10 might help to explain how prostate tumors develop, as well as aid in the development of interventions that reduce prostate cancer risk or treat the disease in patients.

Histology and immunostaining
----------------------------

Mouse prostates were embedded in OCT medium (Histoprep; Fisher Scientific) before sectioning. Analysis of β-gal activity on frozen sections was carried out as described ([@b13-0050366]). Immunofluorescence was performed using chicken anti-*E. coli* β-gal (ab9361; Abcam), rabbit anti-mouse CK5 (AF 138; Covance), rat anti-mouse CK8 (TROMA-1 antibody; Developmental Studies Hybridoma Bank, University of Iowa), and rabbit anti-mouse Nkx3.1 (a kind gift from Cory Abate-Shen, Columbia University, NY) diluted in goat serum at 4°C overnight. Detection of primary antibody of β-gal, CK5 and CK8 was performed by incubating rhodamine/FITC-labeled goat anti-chicken/rabbit/rat IgY/G (1:100) for 1 hour at room temperature followed by DAPI counterstaining. Detection of Nkx3.1 signal using TSA Plus Fluorescence Systems (PerkinElmer) was carried out as described ([@b25-0050366]).

Statistics
----------

We counted the number of foci that expressed AcP10--β-gal and/or Nkx3.1. Foci contained an average of 15 cells. The total number of 'foci', including expressing and non-expressing cells, was determined by counting the total cell number in a given area and extrapolating to the entire slide. Total cell number was divided by the average size of a focus to give the total number of foci. At least 20 sections were counted for each slide, which was derived from one mouse. A total of four mice were counted. The percent of cells/foci expressing Nkx3.1 was compared between foci, which were positive vs negative for AcP10--β-gal. The Pearson chi-square test (based on the 2×2 table) was used to measure the strength of this difference within each slide. To obtain an 'overall' *P*-value across the four mice, the Mantel-Haenszel chi-square test was used.
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